Qnovia Licenses Novel Antimicrobial Peptide to Combat Antibiotic Resistance
Clinical-stage biopharmaceutical company Qnovia, Inc. has secured a worldwide exclusive license for a novel antimicrobial peptide developed at the University of Virginia. The compound shows potential in addressing the cycle of antibiotic-resistant infections.
Qnovia, Inc., a clinical-stage biopharmaceutical company, has announced it has secured a worldwide exclusive license for a novel antimicrobial peptide from the University of Virginia. This newly licensed therapeutic candidate is intended to break the cycle driving antibiotic-resistant infections, a significant global health challenge.
The peptide, licensed by Qnovia, has demonstrated efficacy against multiple bacterial strains, including those that have developed resistance to existing antibiotics. The company believes this compound has the potential to fill a critical unmet need in the treatment of antimicrobial resistance. The development of this glycopeptide is progressing towards potential therapeutic applications.
Antimicrobial resistance is a growing global concern, with the World Health Organization (WHO) identifying it as a major threat to public health. The development of new antimicrobial drugs is a lengthy and expensive process. Agreements like this license can accelerate the path to bringing new treatment options to patients. Qnovia intends to advance the development of the licensed compound into further clinical studies.